(Q46982725)

English

NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production

scientific article published on 2 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

0 references

author name string

Issaka Yougbaré

1

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

Gilles Boire

2

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

Michelle Roy

3

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

Claire Lugnier

4

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

Eric Rouseau

5

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

publication date

2 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

Canadian Journal of Physiology and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

91

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

5

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

353-361

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Defective cAMP-dependent phosphorylation of intact T lymphocytes in active systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Renal expression of IL-6 and TNFalpha genes in lupus nephritis

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Phosphodiesterase 3 and 4 negatively regulate receptor activator of nuclear factor-kappaB ligand-mediated osteoclast formation by prostaglandin E2.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Is there a future for small molecule drugs in the treatment of rheumatic diseases?

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Inflammatory molecules: a target for treatment of systemic autoimmune diseases

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Lupus, the current therapeutic approaches

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Putting the lid on phosphodiesterase 4

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2012-0233

21 January 2018

Identifiers

10.1139/CJPP-2012-0233

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 December 2017

http://europepmc.org/abstract/MED/23656347

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46982725&oldid=2140874315"